Darren Snellgrove's most recent trade in Halozyme Therapeutics Inc. was a trade of 127,432 Option to Purchase Common Stock done . Disclosure was reported to the exchange on July 1, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Halozyme Therapeutics Inc | Darren Snellgrove | SVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2026 | 127,432 | 127,432 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Darren Snellgrove | SVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2026 | 41,554 | 41,554 | - | - | Restricted Stock Units |